Here are the 10-K annual reports from Avalon GloboCare Corp. (ALBT) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow ALBT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALBT filings page.
Avalon GloboCare filed its annual report describing a pivot from legacy biotech and China operations into two main businesses: the Keto Air consumer breathalyzer and the RPM AI-driven short‑form video platform acquired in December 2025. The company posted a net loss of $18,260,976 in 2025, including $17,518,873 from continuing operations, and its auditors raised substantial doubt about its ability to continue as a going concern.
Cash was only $109,091 at December 31, 2025 against a working capital deficit of $12,651,237 and outstanding debt of about $1.1 million, so Avalon plans to raise additional capital and depends on future revenue from Keto Air and the RPM platform, which is still in beta with Phase 2 targeted for Q3 2026. The company also issued Series E preferred stock valued at $19.5 million to buy RPM, faces potential dilution from several preferred series and convertible notes, and must secure shareholder approval and stay within Nasdaq rules to fully convert the new preferred shares.